You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Harvard Business School
Merck
Boehringer Ingelheim
Medtronic

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 10,383,876

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,383,876
Title:Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Abstract: The present invention relates:--to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-- c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;--to methods of preparing said dihydrochloride salt;--to said dihydrochloride salt for the treatment and/or prophylaxis of a disease;--to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;--to a pharmaceutical composition comprising said dihydrochloride salt; and--to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agents. ##STR00001##
Inventor(s): Peters; Jan-Georg (Solingen, DE), Militzer; Hans-Christian (Odenthal, DE), Muller; Hartwig (Velbert, DE)
Assignee: BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE)
Application Number:14/009,599
Patent Claims:see list of patent claims

Details for Patent 10,383,876

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE) 2031-04-05 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE) 2031-04-05 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE) 2031-04-05 RX Orphan search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21   Start Trial BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE) 2031-04-05 RX search
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25   Start Trial BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE) 2031-04-05 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKesson
Johnson and Johnson
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.